

The Brain Metastases & GBM Interest Group

Facts & Enrollment Information

About the Brain Mets & GBM Interest Group

The Brain Mets & GBM Interest Group (BM-GBM IG) collectively engages in a multidisciplinary dialog to exchange ideas; raise awareness of data and resources; and stimulate translational research toward the development of clinical trials that incorporate radiation sciences for cancer patients with brain metastases and glioblastoma multiforme (GBM). The BM-GBM IG serves as a networking conduit for interaction with the NRG Oncology Brain Tumor Committee, Comprehensive Cancer Network (NCCN) Brain Tumor Committees, key investigators at a global level, as well as relevant industry partners. Operationally, the two subgroups of the BM-GBM IG serve the broader community through publication of white papers and editorials.

Goals

1. To serve as a common platform and forum for the discussion of various pre-clinical translational ideas with a high likelihood of being developed into clinical trial concepts, including evaluation of conventional Phase I-II endpoints, but also including development of novel endpoints, biomarker incorporation, compartmental disease control, novel imaging, patient reported outcomes including quality of life, and neurocognitive function.
2. To assist the NCI disease-specific and other Interest Groups specifically in terms of evaluating concepts for brain metastases with a focus on those from melanoma, lung and breast cancer.

BM-GBM Interest Group Chairpersons

Brain Metastasis subgroup:

Minesh Mehta, MD, FASTRO (Miami Cancer Institute, MineshM@baptisthealth.net)

Michelle Kim, MD (University of Michigan, Michekim@med.umich.edu)

GBM subgroup:

Minesh Mehta, MD, FASTRO (Miami Cancer Institute, MineshM@baptisthealth.net)

Evanthia Galanis, MD (Mayo Clinic Rochester, galanis.evanthia@mayo.edu)

Rupesh Kotecha, MD (Miami Cancer Institute, rupeshk@baptisthealth.net)

Teleconference Schedule

- ☐ The BM-GBM group meets through WebEx on the last Monday of each month at 5pm ET with alternating topics relating to brain metastasis and GBM.
- ☐ The group membership is approximately 65.

Activities and Accomplishments

☐ **Clinical Trials**

1. ATR kinase inhibitor VX970 + WBRT in Brain Metastases from NSCLC (ClinicalTrials.gov Identifier: NCT02589522). (https://clinicaltrials.gov/ct2/show/NCT02589522?term=1.%09ATR+kinase+inhibitor+VX970+%2B+WBRT+in+Brain+Metastases+from+NSCLC.&draw=2&rank=1)
2. Phase 1 and Pharmacology Study of Oral 5-Iodo-2- Pyrimidinone- 2- Deoxyribose (IPdr) as a prodrug for IUdR-Mediated Tumor Radiosensitization in Brain Metastases (ClinicalTrials.gov Identifier: NCT02993146) (https://clinicaltrials.gov/ct2/show/NCT02993146?term=ipdr+brain&draw=2&rank=1).

☐ **Publications**

1. R.S. Bindra, E. Galanis, M.P. Mehta, State of the art: the evolving role of RT in combined modality therapy for GBM, J Neurooncol, 134 (2017) 477-478. (Note: GBM IG Special Issue, refer to additional articles therein).
2. C.A. Kunos, E. Galanis, J. Buchsbaum, Q. Shi, L.C. Strauss, C.N. Coleman, M.M. Ahmed, Radiation-agent combinations for glioblastoma: challenges in drug development and future considerations, J Neurooncol, 134 (2017) 551-557.

Interested in becoming a member of the Brain Mets and GBM Interest Group?

☐ Please Contact the Interest Group Coordinator:

Masoor M. Ahmed, PhD

Radiation Research Program

Division of Cancer Treatment & Diagnosis

National Cancer Institute

Tel: 240 276 5700

Email: mansoor.ahmed@nih.gov